Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling

Tissue engineering combines principles of engineering and biology to generate living tissue equivalents for drug testing, disease modeling, and regenerative medicine. As techniques for reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) and subsequently differentiating them...

Full description

Bibliographic Details
Main Authors: Lu Wang, Vahid Serpooshan, Jianyi Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.621781/full
id doaj-e9d6c862e09c4b389afdee27658dd79b
record_format Article
spelling doaj-e9d6c862e09c4b389afdee27658dd79b2021-02-26T04:39:23ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-02-01810.3389/fcvm.2021.621781621781Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV RemodelingLu Wang0Vahid Serpooshan1Vahid Serpooshan2Vahid Serpooshan3Jianyi Zhang4Department of Biomedical Engineering, School of Medicine and School of Engineering, University of Alabama at Birmingham, Birmingham, AL, United StatesDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, United StatesDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, United StatesChildren's Healthcare of Atlanta, Atlanta, GA, United StatesDepartment of Biomedical Engineering, School of Medicine and School of Engineering, University of Alabama at Birmingham, Birmingham, AL, United StatesTissue engineering combines principles of engineering and biology to generate living tissue equivalents for drug testing, disease modeling, and regenerative medicine. As techniques for reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) and subsequently differentiating them into cardiomyocytes and other cardiac cells have become increasingly efficient, progress toward the development of engineered human cardiac muscle patch (hCMP) and heart tissue analogs has accelerated. A few pilot clinical studies in patients with post-infarction LV remodeling have been already approved. Conventional methods for hCMP fabrication include suspending cells within scaffolds, consisting of biocompatible materials, or growing two-dimensional sheets that can be stacked to form multilayered constructs. More recently, advanced technologies, such as micropatterning and three-dimensional bioprinting, have enabled fabrication of hCMP architectures at unprecedented spatiotemporal resolution. However, the studies working on various hCMP-based strategies for in vivo tissue repair face several major obstacles, including the inadequate scalability for clinical applications, poor integration and engraftment rate, and the lack of functional vasculature. Here, we review many of the recent advancements and key concerns in cardiac tissue engineering, focusing primarily on the production of hCMPs at clinical/industrial scales that are suitable for administration to patients with myocardial disease. The wide variety of cardiac cell types and sources that are applicable to hCMP biomanufacturing are elaborated. Finally, some of the key challenges remaining in the field and potential future directions to address these obstacles are discussed.https://www.frontiersin.org/articles/10.3389/fcvm.2021.621781/fulltissue engineeringcardiac patchmyocardiumheart failuremyocardial infarctionregenerative medicine
collection DOAJ
language English
format Article
sources DOAJ
author Lu Wang
Vahid Serpooshan
Vahid Serpooshan
Vahid Serpooshan
Jianyi Zhang
spellingShingle Lu Wang
Vahid Serpooshan
Vahid Serpooshan
Vahid Serpooshan
Jianyi Zhang
Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
Frontiers in Cardiovascular Medicine
tissue engineering
cardiac patch
myocardium
heart failure
myocardial infarction
regenerative medicine
author_facet Lu Wang
Vahid Serpooshan
Vahid Serpooshan
Vahid Serpooshan
Jianyi Zhang
author_sort Lu Wang
title Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
title_short Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
title_full Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
title_fullStr Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
title_full_unstemmed Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling
title_sort engineering human cardiac muscle patch constructs for prevention of post-infarction lv remodeling
publisher Frontiers Media S.A.
series Frontiers in Cardiovascular Medicine
issn 2297-055X
publishDate 2021-02-01
description Tissue engineering combines principles of engineering and biology to generate living tissue equivalents for drug testing, disease modeling, and regenerative medicine. As techniques for reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) and subsequently differentiating them into cardiomyocytes and other cardiac cells have become increasingly efficient, progress toward the development of engineered human cardiac muscle patch (hCMP) and heart tissue analogs has accelerated. A few pilot clinical studies in patients with post-infarction LV remodeling have been already approved. Conventional methods for hCMP fabrication include suspending cells within scaffolds, consisting of biocompatible materials, or growing two-dimensional sheets that can be stacked to form multilayered constructs. More recently, advanced technologies, such as micropatterning and three-dimensional bioprinting, have enabled fabrication of hCMP architectures at unprecedented spatiotemporal resolution. However, the studies working on various hCMP-based strategies for in vivo tissue repair face several major obstacles, including the inadequate scalability for clinical applications, poor integration and engraftment rate, and the lack of functional vasculature. Here, we review many of the recent advancements and key concerns in cardiac tissue engineering, focusing primarily on the production of hCMPs at clinical/industrial scales that are suitable for administration to patients with myocardial disease. The wide variety of cardiac cell types and sources that are applicable to hCMP biomanufacturing are elaborated. Finally, some of the key challenges remaining in the field and potential future directions to address these obstacles are discussed.
topic tissue engineering
cardiac patch
myocardium
heart failure
myocardial infarction
regenerative medicine
url https://www.frontiersin.org/articles/10.3389/fcvm.2021.621781/full
work_keys_str_mv AT luwang engineeringhumancardiacmusclepatchconstructsforpreventionofpostinfarctionlvremodeling
AT vahidserpooshan engineeringhumancardiacmusclepatchconstructsforpreventionofpostinfarctionlvremodeling
AT vahidserpooshan engineeringhumancardiacmusclepatchconstructsforpreventionofpostinfarctionlvremodeling
AT vahidserpooshan engineeringhumancardiacmusclepatchconstructsforpreventionofpostinfarctionlvremodeling
AT jianyizhang engineeringhumancardiacmusclepatchconstructsforpreventionofpostinfarctionlvremodeling
_version_ 1724250029201293312